October 14, 2021

In Re: Niaspan Antitrust Litigation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


  1. June 05, 2023

    3rd Circ. Rejects Rehearing Bid From Niaspan Buyers

    The Third Circuit on Monday refused a rehearing bid from Niaspan buyers accusing AbbVie Inc. and Teva Pharmaceuticals Ltd. of scheming to delay a generic version of the cholesterol drug, after an appeals panel found the lower court was right not to certify a class of insurance plans and other end payors.

9 other articles on this case. View all »


Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!